Login | Register

Abraxane Improves Survival Among Pancreatic Cancer Patients

Celegene Corp's drug Abraxane (paclitaxel protein-bound particles for injectable suspension) was found to be effective at improving overall survival among pancreatic cancer patients when combined with chemotherapy, according to results from the drug's phase III clinical trial. Even though Pancreatic cancer is a relatively uncommon form of cancer - making up only 2...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *